Archive for March, 2010
Cell Therapeutics Looking More Like Sell Therapeutics (CTIC)
Submitted by BioHealth Investor Blog
Cell Therapeutics, Inc. (NASDAQ: CTIC) is about to get to show traders and speculative investors the pleasure and pain in the world of chasing ten-baggers in speculative biotech stocks. The stock has developed a cult following, as you would expect in a company with a share price under $1.00 and a [...]
Somaxon, The Ten-Bagger Chase (SOMX, SNY)
Submitted by BioHealth Investor Blog
There is a new weapon in the war on insomnia, and one which does not appear to have the drug dependence and the nasty side-effects associated with many other sleep aids. Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) announced this morning that the FDA has approved the New Drug Application for Silenor as [...]
Teva Could Be Seeking Mega-Cap Status (TEVA, PFE, NVS, MRK, SNY)
Submitted by BioHealth Investor Blog
Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) is slowly becoming one of the biggest drug makers in the world. This morning the company is up on the news that it won the bidding process to acquire German generic drug maker Ratiopharm GmbH. The price tag: 3.6 billion Euros, or about $5 billion [...]
Abraxis Looks Promising in Lung Cancer War (ABII)
Submitted by BioHealth Investor Blog
Abraxis BioScience, Inc. (NASDAQ: ABII) is one of the top biotech gainers this morning. The company announced that its key ABRAXANE met the primary endpoint in a Phase 3 trial for advanced non-small cell lung cancer.
The company’s randomized Phase 3 clinical trial comparing ABRAXANE, the company’s protein-bound paclitaxel, along with with [...]
StemCells Scores New Stem Cell Patent (STEM)
Submitted by BioHealth Investor Blog
StemCells, Inc. (NASDAQ: STEM) has a new stem cell patent. For rats, issued in the United Kingdom. The company issued a release showing that the United Kingdom Intellectual Property Office granted patent number GB2451523.
The patent has broad claims covering true rat stem cells and genetically engineered rats derived from these cells, [...]
Stem Cells Versus Aging, Fountain of Youth (BTIM, GERN, ACTC)
Submitted by BioHealth Investor Blog
How many movies and legends are based upon eternal youth? Hundreds or thousands for sure. BioTime, Inc. (NYSE Amex: BTIM) is seeing a massive surge of interest today after the company announced a “Peer-Reviewed Scientific Publication on the Reversal of the Developmental Aging of Normal Human Cells.”
The company is a small-cap [...]
The End of Free Drug Pricing in Germany?
Submitted by THE HEALTH ECONOMICS BLOG
Dear All,
below article from invivoblog is a nice summary of the issue that was widely discussed yesterday in the German press. I would just like to add that several health ministers before him have made the attempt to implement price regulations, therefore it remains to be seen what the legal [...]
Sequenom Still Seeks Down’s Syndrome Grail (SQNM)
Submitted by BioHealth Investor Blog
Sequenom, Inc. (NASDAQ: SQNM) is trading lower in the after-hours session after the troubled diagnostics company reported its year-end earnings. Because of its recent woes of 2009, the earnings and revenue reports are a true side-show compared to what the company is updating over its pipeline and over its products.
We would [...]
OSI Can’t Stay Indpendent Forever (OSIP)
Submitted by BioHealth Investor Blog
OSI Pharmaceuticals Inc. (NASDAQ: OSIP) is holding up yet again, despite the notion that Astellas Pharma, Inc. of Japan wants to acquire the company. OSI decided to formally reject the $52.00 per share tender offer and is recommending that its shareholders reject the offer while it contacts other parties. Today we [...]
Savient, Gout, and FDA… Back At The Door (SVNT)
Submitted by BioHealth Investor Blog
Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) is from giving up on its KRYSTEXXA as a gout treatment. This morning the company announced that it has resubmitted its Biologics License Application to the FDA. This has been in the news, particularly since the company announced a secondary offering late last year after the [...]
High Hopes on Ariad (ARIA, MRK)
Submitted by BioHealth Investor Blog
Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) is seeing elevated trading today after a presentation and ahead of earnings. The difference here is that Ariad’s increased trading is in both the stock and in the bonds.
Joe Kunkle of OptionsHawk.com noted, “implied volatility is 10% higher to 87.8% as shares gain 2.7%, 4,140 calls [...]
EDAP TMS, Back on the Map (EDAP)
Submitted by BioHealth Investor Blog
EDAP TMS SA (NASDAQ: EDAP) is a French company which makes medical devices for the treatment of urological diseases and the company’s stock is soaring after the company was granted marketing approval of its newly designed, high-end Sonolith I-Sys lithotripsy device by the Japanese Administration. Because this market is still under-served, [...]
EDAP TMS, Back on the Map (EDAP)
Submitted by BioHealth Investor Blog
Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) has a big event on deck this week. This Friday, March 12, is its Prescription Drug User Fee Act (PDUFA) action date for an FDA panel to issue a recommendation on Byetta as the the first once a week treatment for Type II diabetes. The date [...]
Amylin & Friends Brace for Diabetes Review (AMLN, LLY, ALKS)
Submitted by BioHealth Investor Blog
Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) has a big event on deck this week. This Friday, March 12, is its Prescription Drug User Fee Act (PDUFA) action date for an FDA panel to issue a recommendation on Byetta as the the first once a week treatment for Type II diabetes. The date [...]
The Changing Landscape of Biotech Valuations (ACOR, CBST, MNKD, INCY, SGEN, ITMN, IPXL, MRX, SVNT, VPHM)
Submitted by BioHealth Investor Blog
The biotech and biohealth universe is changing in size. In 2008 and 2009, partly due to mergers and partly due to market valuations, there had become a surprisingly small number of biotech stocks which had market capitalization rates of more than $1 billion. At one point there were only about 10 [...]
When Biotech Layoffs Come (XNPT)
Submitted by BioHealth Investor Blog
When conglomerates and consumer products lay off workers and employees, shareholders generally cheer the company for saving money and cutting costs by figuring out productivity measures that milk more output per employee. That leaves more income and ultimately brings more dividends down the road. But biotech firms are far from being [...]
Winning from Boosting Good Cholesterol (RVXCF, RVX, PFE, AZN, MRK)
Submitted by BioHealth Investor Blog
BioHealthInvestor usually sticks to US companies or at least sticks to ADRs for investors. But sometimes there is a much larger bit of data either north of the border or in Europe. There is a company called Resverlogix Corp. which trades in Canada under the ticker ‘RVX’ and the stock also [...]
Talking Biotech ETFs: iShares Nasdaq Biochnology to $100 (IBB, OSIP, MDVN)
Submitted by BioHealth Investor Blog
Today’s price moves in the biotech sector are quite different from what we saw earlier this week. A hostile merger via tender from Astellas for OSI Pharmaceuticals Inc. (NASDAQ: OSIP) got everyone up in arms this week. So much that other investors were going back over buyout candidate notes. We also [...]
Biotech Implosion: Medivation, Alzheimer’s Beats Drug (MDVN, PFE)
Submitted by BioHealth Investor Blog
Medivation, Inc. (NASDAQ: MDVN) is the next biotech implosion. The company’s highly awaited Phase III study on its Alzheimer drug called Dimebon did not meet expectations. It failed to meet primary and secondary endpoints. The problem is that this was hitting 52-week highs yesterday.
The company did note that a separate Phase [...]
More Biotech Buyout or M&A Targets (OSIP, VRTX, AUXL, ITMN, HGSI, CELG, DNDN, ENZN, FACT, PBE, XBI)
Submitted by BioHealth Investor Blog
After today’s hostile Astellas offer for OSI Pharmaceuticals (NASDAQ: OSIP), we have investors and traders alike looking for ‘the next takeover target’ in biotech. Buy now you know that there are many pitfalls in simply looking for biotech stocks to buy because they will be taken over. We have taken a [...]
Hostile Mergers Back in Biotech (OSIP)
Submitted by BioHealth Investor Blog
Mergers are back in biotech…. Astellas Pharma Inc., a global pharmaceutical company in Japan, announced that it will commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals (NASDAQ: OSIP). The direct tender is nothing short of a hostile merger after Astellas said that OSI has [...]
